Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics (Nasdaq: BEAM) reported Q1 2022 financial results, ending with $1.2 billion in cash, cash equivalents, and marketable securities. The company is on track to enroll patients in the BEACON-101 clinical trial and submit IND applications for BEAM-102 and BEAM-201 in the second half of 2022. Beam has initiated a natural history study on sickle cell trait, partnering with the NASCC. R&D expenses decreased to $65.4 million from $190.1 million year-over-year. The net loss improved to $69.2 million from $201.6 million in Q1 2021.
Beam Therapeutics (Nasdaq: BEAM), a biotech firm focused on precision genetic medicines, announced CEO John Evans will speak at two investor conferences in May 2022. The events are the BofA Securities 2022 Healthcare Conference on May 11, at 2:00 PM PT in Las Vegas, and the RBC Capital Markets Global Healthcare Conference on May 17, at 2:35 PM ET in NYC. Live webcasts will be available on their website and archived for 60 days. Beam is advancing gene editing technologies, particularly base editing, to develop therapies for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) announced it will present new preclinical data at the ASGCT Annual Meeting from May 16-19, 2022. The findings focus on the BEAM-301 program for glycogen storage disease type Ia (GSDIa) and a base editing program for alpha-1 antitrypsin deficiency. Data indicate that BEAM-301 demonstrates significant liver editing improvements, enhancing metabolic parameters and survival in mouse models. Additionally, Beam's proprietary lipid nanoparticle (LNP) technology shows promise for delivering mRNA to immune cells, offering potential advancements in immunology and oncology.
Beam Therapeutics (Nasdaq: BEAM) announced its participation in a fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022, at 9:00 a.m. ET. CEO John Evans and Chief Scientific Officer Giuseppe Ciaramella will represent the company. A live webcast will be accessible in the investor section of Beam's website and will be available for 60 days post-event. Beam Therapeutics specializes in precision genetic medicines through base editing, enabling efficient genomic alterations without DNA breaks, supporting its mission to provide lifelong cures.
Beam Therapeutics (Nasdaq: BEAM) will have its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., participate in a fireside chat at the Barclays 2022 Global Healthcare Conference. The event is scheduled for March 15, 2022, at 8:30 a.m. ET, in Miami, FL. A live webcast of the discussion will be available on the company’s investor website and will be archived for 60 days. Beam is focused on precision genetic medicines using its unique base editing technology to develop innovative therapies for serious diseases.
Beam Therapeutics has announced a collaboration with Pfizer, securing $300 million upfront and potential milestone payments totaling up to $1.35 billion. This partnership aims to advance their base editing programs targeting rare genetic diseases. The company plans to initiate the BEAM-101 clinical trial for sickle cell disease in H2 2022, alongside an IND submission for BEAM-102. Beam's cash position stands at $1.2 billion, supporting its ambitious pipeline, which includes multiple anticipated milestones in 2022 for various treatments.
Beam Therapeutics Inc. (Nasdaq: BEAM) announced that CEO John Evans will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET. A live webcast will be available on their investor website and archived for 60 days. Beam Therapeutics specializes in precision genetic medicines using base editing technology, targeting precise genetic changes without damaging DNA. The company aims to create life-long cures for serious diseases through advanced gene editing and manufacturing capabilities.
Beam Therapeutics and Pfizer have entered a four-year collaboration aimed at developing precision genetic medicines for rare genetic diseases. This partnership will leverage Beam's base editing and delivery technologies, combining them with Pfizer's expertise in drug development. Beam will receive an upfront payment of $300 million and is eligible for milestone payments totaling up to $1.35 billion. The collaboration will focus on three undisclosed targets, with the possibility for co-development and commercialization of one program.
Pfizer (PFE) and Beam Therapeutics (BEAM) announced a four-year research collaboration to develop in vivo base editing programs targeting rare genetic diseases. Beam will receive an upfront payment of $300 million and may earn up to $1.35 billion through future milestone payments. The collaboration aims to advance innovative therapies using Beam's base editing and delivery technologies combined with Pfizer's drug development expertise. This partnership reflects a commitment to addressing unmet medical needs for patients with genetic disorders.
Beam Therapeutics (Nasdaq: BEAM) has announced significant milestones for 2022, including the anticipated enrollment of the first subject in the BEAM-101 Phase 1/2 clinical trial for sickle cell disease in the second half of the year. The company introduced BEAM-301 as its fourth development candidate aimed at treating Glycogen Storage Disease Type Ia. Other key developments involve plans to nominate two additional candidates and present business updates at the J.P. Morgan Healthcare Conference on January 10, 2022. Beam focuses on pioneering precision genetic medicines through base editing technology.